幽门螺杆菌napA基因在乳酸菌中的表达及免疫原性分析

为在乳酸菌中表达幽门螺杆菌（Helicobacter pylori,H.pylori）中性粒细胞激活蛋白(NAP),口服免疫小鼠后检测其免疫原性。在实验中利用了分子克隆技术构建携带nap基因的重组原核表达质粒pNICE:secnap,将重组质粒转化乳酸菌NZ9000株,筛选鉴定阳性菌落,诱导表达的NAP蛋白用SDSPAGE和Western blot进行鉴定。将雌性ICR（CV级）小鼠随机分为4组,分别用PBS、携带空质粒的乳酸菌、携带pNICE:secnap的乳酸菌、灭活的H.pylori 灌胃。免疫7次后检测其特异性IgG和IgA的产生。成功扩增了nap基因并构建了重组原核表达质粒pNICE:secnap,转化乳酸菌NZ9000后经nisin诱导可表达Mr约17kDa的重组蛋白,表达量约占菌体总蛋白量的9.5%,表达的蛋白能与兔抗H.pylori 血清特异性反应,具有良好的免疫原性。携带pNICE:secnap质粒的乳酸菌刺激产生的IgG水平明显高于携带空质粒组,与灭活H.pylori组没有明显的差异,但其刺激产生的IgA水平明显高于其他组。以上结果说明表达NAP蛋白的乳酸菌口服免疫小鼠后,能够刺激小鼠产生特异的IgG和IgA,对幽门螺杆菌疫苗的研究开发具有理论意义。为乳酸菌作为抗原递送载体的研究和H.pylori口服疫苗的开发提供了一定的实验基础。     

幽门螺杆菌热休克蛋白A在乳酸乳球菌中的表达及免疫学活性分析

目的构建含幽门螺杆菌(H.pylori)热休克蛋白A编码基因的重组载体,并电转入乳酸乳球菌MG1363,表达目的蛋白并分析其免疫原性,为H.pylori基因工程口服疫苗的研究和开发奠定基础。方法以H.py-loriNCTC 11637株基因组DNA为模板,PCR扩增hspA基因,并克隆至乳酸乳球菌表达载体pMG36e中。将重组质粒转化E.coliDH5α,经鉴定的阳性重组质粒命名为pMG36e/hspA。以电穿孔法将pMG36e/hspA转化乳酸乳球菌MG1363并用Western blot检测HspA蛋白的表达。结果克隆重组后得到pMG36e/hspA。将pMG36e/hspA电转化MG1363后,收集菌体蛋白进行Western blot分析,在HspA的相对分子质量(Mr≈13 kDa)处出现特异性条带。结论首次成功构建了表达H.pyloriHspA的重组乳酸乳球菌MG1363,为进一步口服疫苗的相关研究奠定了基础。     

幽门螺杆菌热休克蛋白A基因的克隆,表达及免疫原性 …

幽门螺杆菌的感染可以诱发人体产生胃炎和消化性溃疡,其组成成分热休克蛋白Ａ可刺激机体产生保护性的免疫反应,用ＰＣＲ方法从幽门螺杆菌的染色体ＤＮＡ上扩增出ＨｓｐＡ基因片段,将其插入原核表达载体ｐＥＴ－２２ｂ（＋）中,并在ＢＬ２１（ＤＥ３）大肠杆菌表达。经测序Ｈｓｐ基因片段有３５４ｂｐ组成,可编码１１８个氨基酸残基的多肽。     

幽门螺杆菌热休克蛋白A基因的克隆、表达及免疫原性研究

幽门螺杆菌的感染可诱发人体产生胃炎和消化性溃疡,其组成成分热休克蛋白Ａ（ＨｓｐＡ）可刺激机体产生保护性的免疫反应。用ＰＣＲ方法从幽门螺杆菌的染色体ＤＮＡ上扩增出ＨｓｐＡ基因片段,将其插入原核表达载体ｐＥＴ２２ｂ（＋）中,并在ＢＬ２１（ＤＥ３）大肠杆菌表达。经测序ＨｓｐＡ基因片段有３５４ｂｐ组成,可编码１１８个氨基酸残基的多肽。ＳＤＳＰＡＧＥ和免疫印迹分析检测发现,ＨｓｐＡ基因表达的蛋白质分子量约为１５ｋＤ,并证实该重组蛋白质可以被幽门螺杆菌感染阳性患者的血清所识别,同时将其免疫小鼠可刺激机体产生抗该重组蛋白质的抗体。ＨｓｐＡ有可能作为一种有效的蛋白质疫苗用于幽门螺杆菌感染的预防和治疗。     

幽门螺杆菌重组vacA-CtxB蛋白的原核表达及免疫学研究

目的 原核表达幽门螺杆菌pQE-vctB（含H. pylori细胞空泡毒素毒性片段与霍乱毒素B亚单位的融合基因）在E. coil DH5α中诱导表达,以获得重组蛋白,鉴定其抗原性和免疫原性,为制备防治H. pylori感染的口服疫苗奠定基础。方法 （1）pQE-vctB转化E. coli DH5α,IPTG诱导表达重组蛋白VCTB,Western blotting分析抗原性,镍离子柱纯化。（2）重组蛋白VCTB口服免疫小鼠,ELISA检测小鼠血清特异性IgG、小肠冲洗液IgA,以鉴定其免疫原性。结果 重组蛋白VCTB经SDS-PAGE分析相对分子量（Mr）约为40 kD,亲和层析后可获得纯度为92%以上的蛋白。Western blot分析显示能与VacA抗血清反应。ELISA检测显示,免疫小鼠的血清特异性抗体IgG,肠粘液IgA显著高于VacA对照组（P<0.01）。结论 vacA和ctxB融合基因原核表达质粒转化E. coli DH5α表达菌获得了重组蛋白VCTB,表达量较高,纯度较高,有良好的抗原性和免疫原性,口服免疫小鼠可明显提高其免疫效果,产生较高水平的IgA,可用于制备防治H. pylori感染的口服疫苗。     

表达猪传染性胃肠炎病毒S基因的重组乳酸乳球菌的构建及免疫原性分析

根据猪传染性胃肠炎病毒纤突(S)蛋白的全基因序列及表达载体质粒的基因融合特点,设计一对引物,进行PCR扩增,获得含有TGEVS基因4个主要抗原位点的约2000bp的目的片段,将其与分泌表达的载体质粒pNZ8112进行连接,通过电击转化进入宿主菌乳酸乳球菌NZ9000细胞内,在乳链菌肽(Nisin)的诱导下进行表达,通过SDS-PAGE和Western blot分析,表明TGEVS蛋白在乳酸乳球菌中获得表达,所表达的TGEVS蛋白具有与TGE病毒一样的抗原特异性。间接免疫荧光试验表明重组菌表达蛋白定位于菌体表面。将表达TGEVS蛋白的重组乳酸乳球菌及空质粒菌株分别口服免疫BALB/c小鼠,收集粪便样品进行抗体检测,结果表明分泌型的重组菌pNZ8112-Sa/NZ9000免疫小鼠能够产生明显的抗TGEVsIgA抗体。     

含幽门螺杆菌CagA、UreB蛋白与霍乱肠毒素B亚单位（CTB）融合基因的植物表达载体的构建及遗传转化

幽门螺旋杆菌(Helicobacter pylori,Hp)感染是慢性胃炎和消化性溃疡的主要病因,与胃癌和胃粘膜相关淋巴组织(MALT)淋巴瘤的发生也密切相关。目前所用的疫苗制造成本高、运输费用贵,然而利用转基因植物生产的植物疫苗成本低廉、服用方便是现有疫苗的良好替代品。将Hp相关蛋白与免疫佐剂CTB的融合基因(ctb-linker-cagA和ctb-linker-ureB)利用PCR、酶切、连接等一系列方法从载体p1300-WxCLCN和p1300-WxCLUN中重组到载体pCAMBIA2301中(含35S启动子),重组载体分别命名为p2301-35SCLCN和p2301-35SCLUN。通过冻融法将载体导入农杆菌EHA105菌株中,以农杆菌介导的方法,将重组载体p2301-35SCLCN和p2301-35SCLUN转化烟草黄苗榆和心叶烟,获得了具有卡那霉素抗性再生植株,经过酶切、PCR、GUS染色和PCR-Southern鉴定结果表明,目的基因分别正确插入载体中并稳定整合到植株中,为利用植物反应器生产幽门螺杆菌疫苗奠定了坚实的基础。     

猪A组轮状病毒Vp6基因与乳酸菌非抗性表达载体的重组及在大肠杆菌中的表达

以猪A组轮状病毒mRNA为模板,应用反转录聚合酶链式反应(RT-PCR)技术,扩增了1194bp的Vp6基因,通过T-A克隆技术,将PCR产物克隆至克隆载体pGEM-TVector中,构建克隆质粒pGEM-T-Vp6。用SacⅠ和KpnⅠ双酶切pGEM-T-Vp6和以胸苷酸合成酶基因(thymidylate synthase,thyA)为选择压力的非抗生素抗性的穿梭表达载体pW425t,并将纯化的Vp6基因亚克隆至表达载体pW425t中,构建出可以在乳酸菌与大肠杆菌之间穿梭表达的原核表达重组质粒pW425t-Vp6。将pW425t-Vp6转化至thyA基因缺陷型的大肠杆菌感受态E.coliX13中,经生长功能弥补筛选阳性克隆,通过SDS-PAGE分析,可见约44.88kD的融合蛋白。由Western blot分析,表明该蛋白具有与轮状病毒多克隆抗体的反应原性,从而为pW425t-Vp6在乳酸菌受体菌株中表达提供理论基础和实验依据。     

幽门螺杆菌katA基因功能及其在耐受氧化损伤中的作用分析

【目的】过氧化氢酶（KatA）是幽门螺杆菌编码的重要毒力因子,在抵抗宿主免疫杀伤和疫苗研发等方面具有重要功能。为了鉴定幽门螺杆菌 KatA 的酶学特性,并分析其在幽门螺杆菌氧化耐受中的功能。【方法】首先,从幽门螺杆菌临床耐药菌株 Hp＿G272 基因组中分离 katA 基因,并在大肠杆菌中克隆表达、分离纯化KatA^G272 蛋白;然后,利用 CAT 检测试剂盒体外分析 KatA^G272 的过氧化氢酶活性;其次,利用同源重组技术构建 katA 基因工程菌株,包括敲除菌株和回补菌株;最后,通过比较野生菌株与工程菌株生长表型差异、分解过氧化氢能力差异及耐受过氧化氢能力差异,阐述 katA 基因的功能及其在幽门螺杆菌耐受氧化损伤中的作用。【结果】在大肠杆菌中成功克隆表达并分离纯化 KatA^G272,体外酶学分析表明,KatA^G272 是一类嗜酸性过氧化氢酶,基因敲除分析表明,敲除该基因幽门螺杆菌丧失分解和耐受过氧化氢的能力,而回补该基因幽门螺杆菌回复分解和耐受过氧化氢的能力。【结论】katA 基因是幽门螺杆菌分解和耐受过氧化氢的唯一功能基因,在幽门螺杆菌氧化耐受中具有重要功能。     

人胰岛素基因在乳酸菌中的表达及其对非肥胖糖尿病(NOD)小鼠的作用

为实现人胰岛素基因在乳酸菌中的表达及探索其用作口服疫苗治疗Ⅰ型糖尿病(T1DM)的可行性,首先将人胰岛素基因密码子替换为乳酸菌偏爱密码子,同时在A,B链序列间加入连接短肽序列,经引物退火拼接合成人胰岛素基因。克隆至乳酸菌表达载体中后,利用电击转化法实现了带信号肽SPUsp45的人胰岛素基因在乳酸乳球菌(Lactococcus lactis)MG1363和干酪乳杆菌(Lactobacillus casei)ATCC27092中的表达。Western blot检测显示重组胰岛素位于细胞壁上,当菌体生长到OD600为0.4时达到最大表达量。用含有表达重组人胰岛素的Lactobacillus caseiATCC27092/pSW501菌体饲喂非肥胖糖尿病(NOD)小鼠,发现可刺激小鼠产生特异性抗体,同时使与免疫耐受相关的细胞因子IL-4水平明显升高(38.583±2.083pg/mL,P<0.05),提示其对NOD小鼠产生免疫耐受有一定的作用,为研制乳酸菌口服疫苗防治T1DM的可行性进行了有益的探索。     

Expression of Helicobacter pylori cag12 gene in Lactococcus lactis MG1363 and its oral administration to induce systemic anti-Cag12 immune response in mice

To develop an oral vaccine against Helicobacter pylori infection, we have expressed the H. pylori cag12 (HP0532) gene, encoding the outer membrane protein Cag12 (31 kDa), in a live delivery vehicle Lactococcus lactis. The cag12 gene was amplified by polymerase chain reaction (PCR) using the genomic DNA of H. pylori K51 isolated from Korean patients. DNA sequence analysis revealed that the cag12 gene of H. pylori K51 has 98.1 and 97.4% identity with individual cag12 genes of the H. pylori 26695 and J99, respectively. The GST–Cag12 fusion protein, produced using the Escherichia coli expression system, was used to raise a rat polyclonal anti-Cag12 antibody. The PCR-amplified cag12 gene of H. pylori K51 was cloned in the E. coli–L. lactis shuttle vector (pMG36e) and transformed into L. lactis. Western blot analysis demonstrated that the Cag12 protein was expressed in the L. lactis transformant, with a maximum level at the log phase without extracelluar secretion. The oral administration of the transformant into mice resulted in the generation of the anti-Cag12 antibody in serum in two out of five cases. These results suggest that the recombinant L. lactis, which expresses Cag12, may be applicable as an oral vaccine to induce protective immunity against H. pylori.     

Expression of a hepatitis A virus antigen in Lactococcus lactis and Escherichia coli and evaluation of its immunogenicity

An epidemic shift in Hepatitis A virus (HAV) infection has been observed in recent years in rapidly developing countries, with increasing numbers of severe adult cases which has led to renewed interest in vaccination. Our approach in vaccine development uses recombinant expression of the highly immunogenic HAV antigen VP1-P2a in food-grade lactic acid bacterium Lactococcus lactis and in Escherichia coli. We used genetic constructs that enable nisin-controlled expression of the antigen in L. lactis in three different forms: (a) intracellularly, (b) on the bacterial surface and (c) on the bacterial surface fused with the fragment of the E. coli flagellin molecule that can act as a molecular adjuvant. Expression of the two surface forms of the antigen was achieved in L. lactis, and the resulting antigen-displaying bacteria were administered orally to mice. Half the animals in each of the two groups developed specific IgGs, with titers increasing over time and reaching 1:422 without flagellin and 1:320 with flagellin. A much higher titer 1:25,803 was observed with the parenterally administered antigen, which was purified from E. coli. With the latter, a significant mucosal IgA response was also observed. Despite significant titers, the IgGs elicited with oral or parenteral administration could not prevent HAV from infecting cells in a virus neutralization assay, suggesting that the antibodies cannot recognize viral surface epitopes. Nevertheless, orally administered HAV antigen expressed in L. lactis elicited significant systemic humoral immune response showing the feasibility for development of effective HAV vaccine for mucosal delivery.     

大肠埃希菌Mn-SOD在乳酸乳球菌中的表达

本文根据GenBank中报道的大肠埃希菌MG1655全基因组DNA序列中SOD的编码基因序列设计引物,PCR扩增大肠埃希菌锰超氧化物歧化酶(Mn-SOD)基因,并将其克隆入原核高效表达质粒载体pBV220中构建重组质粒pBV220-sod,并将其电转入乳酸乳球菌MG1363中获得了成功表达,为SOD发酵奶的研制奠定了基础。     

Expression of a beta-galactosidase gene from Clostridium acetobutylicum in Lactococcus lactis subsp. lactis

A beta-galactosidase gene from Clostridium acetobutylicum NCIB 2951 was expressed after cloning into pSA3 and electroporation into derivatives of Lactococcus lactis subsp. lactis strains H1 and 7962. When the clostridial gene was introduced into a plasmid-free derivative of the starter-type Lact. lactis subsp. lactis strain H1, the resulting construct had high beta-galactosidase activity but utilized lactose only slightly faster than the recipient. beta-galactosidase activity in the construct decreased by over 50% if the 63 kb Lac plasmid pDI21 was also present with the beta-galactosidase gene. Growth rates of Lac+ H1 and 7962 derivatives were not affected after introduction of the clostridial beta-galactosidase, even though beta-galactosidase activity in a 7962 construct was more than double that of the wild-type strain. When pDI21 was electroporated into a plasmid-free variant of strain 7962, the recombinant had high phospho-beta-galactosidase activity and a growth rate equal to that of the H1 wild-type strain. The H1 plasmid-free strain grew slowly in T5 complex medium, utilized lactose and contained low phospho-beta-galactosidase activity. We suggest that beta-galactosidase expression can be regulated by the lactose phosphotransferase system-tagatose pathway and that Lact. lactis subsp. lactis strain H1 has an inefficient permease for lactose and contains chromosomally-encoded phospho-beta-galactosidase genes.     

Expression of Helicobacter pylori ggt gene in baculovirus expression system and activity analysis of its products

The gamma-glutamyltranspeptidase (GGT) of Helicobacter pylori (HpGT) is a newly found virulence factor. In an approach to gain insight into the gene function, the four domains of the HpGT were cloned and expressed in baculovirus expression system. The results of a functional assay showed that the HpGT products acted as GGT, even when the N-terminal 380 amino acids were deleted. However, only the full length open reading frame (ORF) of the HpGT gene was apparently effective on cell growth. This result indicated that the products of the full length ORF might have an important role in gastric carcinogenesis. In this paper, we are the first to report that changes of mitochondrial membrane potential can be detected using 5, 5', 6, 6'-tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazole carbocyanine iodide (JC-1) staining in insect cells.     

鼠疫抗原LcrV在乳酸乳球菌中的表达与鉴定

目的以乳酸乳球菌(Lactococcus lactis)为载体,将鼠疫抗原LcrV基因导入乳酸乳球菌内,构建重组肠道微生态菌株,作为黏膜免疫疫苗的先期探索和尝试。方法采用酸诱导P170启动子,乳酸乳球菌本身的SP310mut2信号肽,将鼠疫杆菌LcrV抗原结构基因克隆到质粒pAM J397上,电转化感受态Lactococcus lactis PSM565。结果经重组子PCR鉴定,SDS-PAGE检测,W estern-b lot鉴定,在Lactococcus lactisPSM565/pAM J397-V培养基上清中获得了38 kD的鼠疫抗原LcrV蛋白。结论在乳酸乳球菌中成功表达了鼠疫V抗原,为下一步鼠疫黏膜疫苗的研制打下基础。     

Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B

To determine whether a protective immune response could be elicited by oral delivery of a recombinant live bacterial vaccine, Helicobacter pylori urease subunit B (UreB) was expressed for extracellular expression in food-grade bacterium Lactococcus lactis . The UreB-producing strains were then administered orally to mice, and the immune response to UreB was examined. Orally vaccinated mice produced a significant UreB-specific serum immunoglobulin G (IgG) response. Specific anti-UreB IgA responses could be detected in the feces of mice immunized with the secreting lactococcal strain. Mice vaccinated orally were significantly protected against gastric Helicobacter infection following a challenge with H. pylori strain SS1. In conclusion, mucosal vaccination with L. lactis expressing UreB produced serum IgG and UreB-specific fecal IgA, and prevented gastric infection with H. pylori .